Annotation Detail
Information
- Associated Genes
- NRAS
- Associated Variants
-
NRAS Q61
NRAS Q61 - Associated Disease
- skin melanoma
- Source Database
- CIViC Evidence
- Description
- Phase 1 trial in 57 patients with advanced cancers treated with selumetinib. 4 melanoma patients had NRAS Q61 mutations. One patient with NRAS mutation had 70% tumor shrinkage after three cycles of selumetinib (AZD6244) but developed symptomatic brain metastases before confirmatory scans could be performed.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1473
- Gene URL
- https://civic.genome.wustl.edu/links/genes/36
- Variant URL
- https://civic.genome.wustl.edu/links/variants/94
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Skin Melanoma
- Evidence Direction
- Supports
- Drug
- Selumetinib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 18390968
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Selumetinib | Sensitivity | true |